GALIMEDIX THERAPEUTICS
Galimedix Therapeutics is an ophthalmic pharmaceutical company that develops novel and transformative treatments.
GALIMEDIX THERAPEUTICS
Industry:
Pharmaceutical Therapeutics
Address:
Kensington, Maryland, United States
Country:
United States
Website Url:
http://www.galimedix.com
Total Employee:
1+
Status:
Active
Contact:
972-4-9905139
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Apache
Official Site Inspections
http://www.galimedix.com
- Host name: mi3-ts107.a2hosting.com
- IP address: 66.198.240.20
- Location: Ann Arbor United States
- Latitude: 42.2503
- Longitude: -83.8393
- Metro Code: 505
- Timezone: America/Detroit
- Postal: 48106
More informations about "Galimedix Therapeutics"
About us โ Galimedix Therapeutics
Galimedix is a Phase 2 clinical-stage company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Founded by a seasoned and highly dedicated โฆSee details»
Galimedix Therapeutics
At Galimedix, we are working to improve the lives of millions of patients worldwide by developing game-changing drugs to treat major neurodegenerative diseases where amyloid beta plays a โฆSee details»
Galimedix Therapeutics - Crunchbase Company Profile & Funding
Galimedix Therapeutics is located in Kensington, Maryland, United States. Who invested in Galimedix Therapeutics? Galimedix Therapeutics is funded by InFocus Capital Partners. โฆSee details»
Galimedix Therapeutics, Inc. - LinkedIn
Galimedix Therapeutics is a Phase 2 neuropharmaceutical company developing novel first-in-class drugs with ground-breaking potential to slow or stop the progression of neurodegeneration and to ...See details»
Contact โ Galimedix Therapeutics
Email: [email protected]. Fields marked with an * are required. Name * Company Email * Telephone Message * Mailing List PLEASE CHECK here if you would like to be added to our โฆSee details»
Galimedix - LifeScienceHistory.com
Galimedix is a Phase 2 clinical-stage company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. โฆSee details»
Galimedix Therapeutics GmbH - Innovations- und Gründerzentrum ...
Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and โฆSee details»
Galimedix Therapeutics, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Galimedix Therapeutics, Inc. of Kensington, MD. Get the latest business insights from Dun & Bradstreet.See details»
Galimedix Therapeutics - Funding, Financials, Valuation & Investors
Galimedix Therapeutics is an ophthalmic pharmaceutical company that develops novel and transformative treatments. New. Resources. Advanced Search. Start Free Trial . ... How much โฆSee details»
Galimedix Therapeutics - VentureRadar
Galimedix is a clinical stage pharmaceutical and ophthalmic company developing transformative treatments based on a novel mechanism of action directed to the common cause for several โฆSee details»
Galimedix Therapeutics - PitchBook
Galimedix Therapeutics is headquartered in Kensington, MD. What is the size of Galimedix Therapeutics? Galimedix Therapeutics has 9 total employees. What industry is Galimedix โฆSee details»
Galimedix Therapeutics, Inc. (Galimedix Therapeutics, Inc.) - ่ฏ็ฉ็ฎก โฆ
Galimedix holds global rights to GAL-201. About Galimedix Therapeutics, Inc. Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective โฆSee details»
Théa and Galimedix enter into Licensing Agreement | Théa
Galimedix will grant TOI exclusive rights for the development and commercialization of GAL-101, Galimedixโs lead disease-modifying compound, for the topical and oral treatment of dry age โฆSee details»
Galimedix GmbH Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Galimedix GmbH of Planegg, Bayern. Get the latest business insights from Dun & Bradstreet.See details»
Partnering โ Galimedix Therapeutics
Galimedix received an upfront technology access fee and is eligible to receive further success-based milestone payments as well as royalties on net sales. While TOI will fully fund the โฆSee details»
Galimedix Therapeutics, Inc. - GoingPublic.de
Galimedix is a Phase 2 clinical-stage private biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious โฆSee details»
Galimedix Therapeutics initiates Phase 1 study with oral small โฆ
Dec 5, 2024 Kensington, MD, USA, December 5, 2024 โ Galimedix Therapeutics, Inc. (โGalimedixโ), a Phase 2 clinical-stage biotechnology company developing novel oral and โฆSee details»
Galimedix Therapeutics GmbH - Innovations- und Gründerzentrum ...
Galimedix verfolgt das Ziel, neurodegenerative Prozesse an ihrem Ursprung zu stoppen und entwickelt bahnbrechende neuroprotektive Therapien zur Behandlung schwerer Augen- und โฆSee details»
BIO-Europe: Galimedix is developing amyloid beta aggregation โฆ
Nov 5, 2024 BIO-Europe: Galimedix is developing amyloid beta aggregation modulators to try to block toxic Aฮฒ upstream of where most others have focused - the lead programs are in โฆSee details»
Métis Nation of Ontario claims vindication while critics dismiss โฆ
1 day ago The Métis Nation of Ontario is claiming vindication after a much-anticipated report supported the presence of seven Métis communities in the province, while opponents are โฆSee details»